Secretory Phospholipase A2-IIA and Cardiovascular Disease

Tom R. Gaunt | O. Franco | A. Hofman | A. Uitterlinden | M. Tobin | D. Lawlor | Mingyao Li | S. Yusuf | J. Boer | J. Mega | B. Horne | N. Samani | A. Hall | P. Braund | M. Farrall | J. Carlquist | Jeffrey L. Anderson | H. Brenner | S. Humphries | A. Hingorani | M. Sabatine | A. Dehghan | D. Rader | M. Guardiola | P. Talmud | P. Whincup | N. Sattar | M. Sandhu | P. de Knijff | D. Rothenbacher | C. Nelson | A. Hamsten | A. Franco‐Cereceda | P. Eriksson | H. Nathoe | U. de Faire | M. Scholz | D. Morrow | A. Nicolaides | J. Jukema | J. Verschuren | J. Pitha | W. Spiering | W. Koenig | H. Watkins | I. Day | S. Mehta | A. Goel | P. van der Harst | L. Folkersen | K. Gertow | F. Veglia | M. Trip | J. Price | K. Khaw | D. Baldassarre | E. Tremoli | M. Kumari | M. Kivimaki | G. Navis | G. Paré | J. Casas | K. Fox | S. Boekholdt | S. Trompet | I. Ford | R. Gansevoort | F. Asselbergs | A. Tybjaerg-hansen | M. Holmes | R. Morris | L. Holdt | D. Teupser | N. Onland-Moret | I. Mateo Leach | J. Cooper | J. Thiery | T. Palmer | B. Keating | N. Danchin | O. Klungel | T. Simon | K. Kuchenbaecker | M. Hofker | M. Leusink | A. Tedgui | J. Palmen | F. Beutner | A. Panayiotou | J. Hubacek | V. Adámková | Z. Mallat | S. Tsimikas | A. H. Maitland‐van der Zee | J. Stephens | A. Olsson | P. Doevendans | M. Cramer | K. Carruthers | G. Schwartz | D. Swerdlow | J. C. Witteman | K. Brunisholz | E. V. van Iperen | G. Hovingh | D. Dallmeier | Kimberly D. Brunisholz | C. L. Haase | H. Exeter | R. Poledne | F. M. van 't Hooft | L. Breitling | S. Kotti | E. Staines-Urias | Jaqueline C. M. Witteman | P. van der harst | J. Piťha | A. Franco-Cereceda | A. Uitterlinden | J. Witteman | A. Goel | A. Hofman | C. Nelson | F. M. van ’t Hooft | J. Cooper

[1]  R. Rosenson,et al.  Phospholipase A2 enzymes and the risk of atherosclerosis. , 2012, European heart journal.

[2]  A. Dominiczak,et al.  Genetic basis of blood pressure and hypertension. , 2012, Trends in genetics : TIG.

[3]  A. Tedgui,et al.  Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes , 2012, Circulation.

[4]  J. Kastelein,et al.  Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial , 2012, Cardiovascular Drugs and Therapy.

[5]  S. Solomon,et al.  Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. , 2011, Clinical chemistry.

[6]  Christopher D. Brown,et al.  Identification, Replication, and Functional Fine-Mapping of Expression Quantitative Trait Loci in Primary Human Liver Tissue , 2011, PLoS genetics.

[7]  R. Rosenson,et al.  Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. , 2011, European heart journal.

[8]  W. Cantor,et al.  The sPLA2 Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) Trial , 2010, Circulation.

[9]  G. Lambeau,et al.  Lipoprotein-Associated and Secreted Phospholipases A2 in Cardiovascular Disease: Roles as Biological Effectors and Biomarkers , 2010, Circulation.

[10]  D. Waters,et al.  Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. , 2010, Journal of the American College of Cardiology.

[11]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[12]  D. Waters,et al.  Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial , 2009, The Lancet.

[13]  Heather L Rick,et al.  Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE−/− Mice , 2009, Journal of cardiovascular pharmacology.

[14]  George Davey Smith,et al.  Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology , 2008, Statistics in medicine.

[15]  D. Lawlor,et al.  Re: Estimation of bias in nongenetic observational studies using "Mendelian triangulation" by Bautista et al. , 2007, Annals of epidemiology.

[16]  R. Luben,et al.  Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and Women: The EPIC-NORFOLK Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[17]  Juan P Casas,et al.  Estimation of bias in nongenetic observational studies using "mendelian triangulation". , 2006, Annals of epidemiology.

[18]  S. Humphries,et al.  Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study. , 2006, Human molecular genetics.

[19]  B. Asselain,et al.  Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. , 2005, Journal of the American College of Cardiology.

[20]  D. Praticò,et al.  Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress Published, JLR Papers in Press, May 16, 2005. DOI 10.1194/jlr.M400469-JLR200 , 2005, Journal of Lipid Research.

[21]  Richard D Riley,et al.  Meta‐analysis of genetic studies using Mendelian randomization—a multivariate approach , 2005, Statistics in medicine.

[22]  N. Day,et al.  Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[23]  Keith R Abrams,et al.  An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization. , 2004, American journal of epidemiology.

[24]  N. Roehm,et al.  Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. , 1999, The Journal of pharmacology and experimental therapeutics.

[25]  Tom R. Gaunt,et al.  Secretory Phospholipase A2-IIA and Cardiovascular Disease , 2013, Journal of the American College of Cardiology.

[26]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.